- 米国企業
- Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd.ENLV
| 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 |
---|
Cash and cash equivalents (note 3) | 11 | 7 | 7 | 4 | 10 | 4 | 6 | 11 | 50 |
---|
Short term deposits (note 4) | 22 | 12 | 3 | - | 0 | 8 | 30 | 10 | 0 |
---|
Marketable securities | - | - | - | - | - | - | - | 63 | - |
---|
Prepaid expenses and other receivables (note 5) | - | - | - | - | - | - | 1 | 2 | 2 |
---|
Total Current Assets | 33 | 20 | 11 | 4 | 10 | 16 | 38 | 86 | 52 |
---|
Property and equipment, net (note 6) | 0 | 0 | 0 | - | 1 | 1 | 1 | 3 | 10 |
---|
Total | - | - | - | - | - | 0 | 1 | 6 | 5 |
---|
Total Non-Current Assets | 0 | 0 | 0 | - | 1 | 1 | 2 | 9 | 15 |
---|
TOTAL ASSETS | 33 | 21 | 11 | 4 | 11 | 18 | 40 | 95 | 68 |
---|
Accounts payable trade (note 14) | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
---|
Accrued expenses and other liabilities, total | - | - | - | - | 1 | 2 | 3 | 4 | 5 |
---|
Total Current Liabilities | 2 | 3 | 2 | 0 | 1 | 6 | 4 | 5 | 7 |
---|
Other long-term Liabilities (note 9) | - | - | - | - | - | 0 | 0 | 5 | 4 |
---|
Total Non-Current Liabilities | - | - | - | - | 0 | 0 | 0 | 5 | 4 |
---|
TOTAL LIABILITIES | - | - | - | - | 1 | 6 | 5 | 10 | 11 |
---|
Ordinary shares of NIS 0.40 par value: (note 11) Authorized: 45,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 18,421,852 and 18,331,507 as of December 31, 2022 and 2021, respectively; | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
---|
Additional paid in capital | 39 | 42 | 48 | 49 | 27 | 37 | 70 | 134 | 137 |
---|
Foreign currency translation reserve | - | - | - | - | -2 | -1 | 1 | 1 | 1 |
---|
Accumulated deficit | -8 | -24 | -40 | -46 | -16 | -26 | -37 | -52 | -83 |
---|
TOTAL SHAREHOLDERS’ EQUITY | 31 | 18 | 9 | 3 | 10 | 11 | 35 | 85 | 57 |
---|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 33 | 21 | 11 | 4 | 11 | 18 | 40 | 95 | 68 |
---|